Effect of sibutramine on weight maintenance after weight loss:: a randomised trial

被引:548
作者
James, WPT
Astrup, A
Finer, N
Hilsted, J
Kopelman, P
Rössner, S
Saris, WHM
Van Gaal, LF
机构
[1] Rowett Res Inst, Aberdeen, Scotland
[2] Royal Vet & Agr Univ, Res Dept Human Nutr, Copenhagen, Denmark
[3] Luton & Dunstable Hosp, Obes Res Ctr, Luton, Beds, England
[4] Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark
[5] Royal London Hosp, Directorate Diabet & Metab, London E1 1BB, England
[6] Huddinge Univ Hosp, Obes Unit, S-14186 Huddinge, Sweden
[7] Rijksunnersiteit Limburg, Nutr Res Ctr, Limburgerhof, Germany
[8] Univ Antwerp Hosp, Dept Endocrinol, Antwerp, Belgium
关键词
D O I
10.1016/S0140-6736(00)03491-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and to enhance the effects of a low-calorie diet for up to a year. We did a randomised, double-blind trial to assess the usefulness of sibutramine in maintaining substantial weight loss over 2 years. Methods Eight European centres recruited 605 obese patients (body-mass index 30-45 kg/m(2)) for a 6-month period of weight loss with sibutramine (10 mg/day) and an individualised 600 kcal/day deficit programme based on measured resting metabolic rates. 467 (77%) patients with more than 5% weight toss were then randomly assigned 10 mg/day sibutramine (n=352) or placebo (n=115) for a further 18 months. Sibutramine was increased up to 20 mg/day if weight regain occurred. The primary outcome measure was the number of patients at year 2 maintaining at least 80% of the weight lost between baseline and month 6. Secondary outcomes included changes in uric acid concentrations and glycaemic and lipid variables. Analysis was by intention to treat. Findings 148 (42%) individuals in the sibutramine group and 58 (50%) in the placebo group dropped out. Of the 204 sibutramine-treated individuals who completed the trial, 89 (43%) maintained 80% or more of their original weight loss, compared with nine (16%) of the 57 individuals in the placebo group (odds ratio 4 . 64, p<0<bullet>001). Patients had substantial decreases over the first 6 months with respect to triglycerides, VLDL cholesterol, insulin, C peptide, and uric acid; these changes were sustained in the sibutramine group but not the placebo group. HDL cholesterol concentrations rose substantially in the second year: overall increases were 20 .7% (sibutramine) and 11 .7% (placebo, p<0<bullet>001). 20 (3%) patients were withdrawn because of increases in blood pressure;in the sibutramine group, systolic blood pressure rose from baseline to 2 years by 0 .1 mm Hg (SD 12 .9), diastolic blood pressure by 2 .3 mm Hg (9 .4), and pulse rate by 4 .1 beats/min (11 .9). Interpretation This individualised management programme achieved weight loss in 77% of obese patients and sustained weight loss in most patients continuing therapy for 2 years. Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for tow concentrations of HDL cholesterol relating to coronary heart disease.
引用
收藏
页码:2119 / 2125
页数:7
相关论文
共 19 条
  • [1] CARDIOVASCULAR-DISEASE RISK PROFILES
    ANDERSON, KM
    ODELL, PM
    WILSON, PWF
    KANNEL, WB
    [J]. AMERICAN HEART JOURNAL, 1991, 121 (01) : 293 - 298
  • [2] Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
    Apfelbaum, M
    Vague, P
    Ziegler, O
    Hanotin, C
    Thomas, F
    Leutenegger, E
    [J]. AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) : 179 - 184
  • [3] ARMITAGE P, 1987, STAT METHODS MED RES, P282
  • [4] BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
  • [5] Sibutramine produces dose-related weight loss
    Bray, GA
    Blackburn, GL
    Ferguson, JM
    Greenway, FL
    Jain, AK
    Mendel, CM
    Mendels, J
    Ryan, DH
    Schwartz, SL
    Scheinbaum, ML
    Seaton, TB
    [J]. OBESITY RESEARCH, 1999, 7 (02): : 189 - 198
  • [6] ANALYSIS OF COVARIANCE USING THE RANK TRANSFORMATION
    CONOVER, WJ
    IMAN, RL
    [J]. BIOMETRICS, 1982, 38 (03) : 715 - 724
  • [7] EFFECTS OF WEIGHT-REDUCTION ON BLOOD-LIPIDS AND LIPOPROTEINS - A METAANALYSIS
    DATTILO, AM
    KRISETHERTON, PM
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1992, 56 (02) : 320 - 328
  • [8] The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
    Hansen, DL
    Toubro, S
    Stock, MJ
    Macdonald, IA
    Astrup, A
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (10) : 1016 - 1024
  • [9] THE EPIDEMIOLOGY OF OBESITY
    HODGE, AM
    ZIMMET, PZ
    [J]. BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1994, 8 (03): : 577 - 599
  • [10] Lauterbach K. W., 2000, International Journal of Obesity, V24, pS99